Filtered By:
Drug: Dexamethasone
This page shows you your search results in order of date. This is page number 9.
Order by Relevance | Date
Total 6413 results found since Jan 2013.
Favipiravir and Ribavirin protect immunocompetent mice from lethal CCHFV infection
In this study, we describe a lethal model of CCHFV infection using a mouse-adapted strain of CCHFV (MA-CCHFV) in adult wild-type male mice. Infected mice developed high viral loads, tissue pathology, inflammatory immune responses before ultimately succumbing to the infection. We used the model to evaluate the protective efficacy of nucleoside analogs monulpiravir, favipiravir, ribavirin, the antibiotic tigecycline and the corticosteroids dexamethasone and methylprednisolone against lethal CCHFV infection. Tigecycline, monulpiravir and the corticosteroids failed to protect mice from lethal MA-CCHFV infection. In contrast, f...
Source: Antiviral Research - August 23, 2023 Category: Virology Authors: Thomas Tipih Kimberly Meade-White Deepashri Rao Trenton Bushmaker Mathew Lewis Carl Shaia Heinz Feldmann David W Hawman Source Type: research
Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma
Haematologica. 2023 Aug 24. doi: 10.3324/haematol.2022.282624. Online ahead of print.ABSTRACTTo improve patient outcomes in the otherwise incurable hematologic malignancy of multiple myeloma (MM), a key paradigm includes initial treatment to establish disease control rapidly followed by maintenance therapy to ensure durability of response with manageable toxicity. However, patient prognosis becomes worse after relapse, and the disease burden and drug toxicities are generally more challenging with subsequent lines of therapy. It is therefore particularly important that patients with newly diagnosed multiple myeloma (NDMM) r...
Source: Haematologica - August 23, 2023 Category: Hematology Authors: Paul G Richardson Brian G Durie Laura Rosi ñol Maria-Victoria Mateos Angela Dispenzieri Philippe Moreau Shaji Kumar Noopur Raje Nikhil Munshi Jacob P Laubach Peter O'Gorman Elizabeth O'Donnell Peter Voorhees Thierry Facon Joan Blad é Sagar Lonial Aurore Source Type: research
Favipiravir and Ribavirin protect immunocompetent mice from lethal CCHFV infection
In this study, we describe a lethal model of CCHFV infection using a mouse-adapted strain of CCHFV (MA-CCHFV) in adult wild-type male mice. Infected mice developed high viral loads, tissue pathology, inflammatory immune responses before ultimately succumbing to the infection. We used the model to evaluate the protective efficacy of nucleoside analogs monulpiravir, favipiravir, ribavirin, the antibiotic tigecycline and the corticosteroids dexamethasone and methylprednisolone against lethal CCHFV infection. Tigecycline, monulpiravir and the corticosteroids failed to protect mice from lethal MA-CCHFV infection. In contrast, f...
Source: Antiviral Research - August 23, 2023 Category: Virology Authors: Thomas Tipih Kimberly Meade-White Deepashri Rao Trenton Bushmaker Mathew Lewis Carl Shaia Heinz Feldmann David W Hawman Source Type: research
Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma
Haematologica. 2023 Aug 24. doi: 10.3324/haematol.2022.282624. Online ahead of print.ABSTRACTTo improve patient outcomes in the otherwise incurable hematologic malignancy of multiple myeloma (MM), a key paradigm includes initial treatment to establish disease control rapidly followed by maintenance therapy to ensure durability of response with manageable toxicity. However, patient prognosis becomes worse after relapse, and the disease burden and drug toxicities are generally more challenging with subsequent lines of therapy. It is therefore particularly important that patients with newly diagnosed multiple myeloma (NDMM) r...
Source: Haematologica - August 23, 2023 Category: Hematology Authors: Paul G Richardson Brian G Durie Laura Rosi ñol Maria-Victoria Mateos Angela Dispenzieri Philippe Moreau Shaji Kumar Noopur Raje Nikhil Munshi Jacob P Laubach Peter O'Gorman Elizabeth O'Donnell Peter Voorhees Thierry Facon Joan Blad é Sagar Lonial Aurore Source Type: research
Favipiravir and Ribavirin protect immunocompetent mice from lethal CCHFV infection
In this study, we describe a lethal model of CCHFV infection using a mouse-adapted strain of CCHFV (MA-CCHFV) in adult wild-type male mice. Infected mice developed high viral loads, tissue pathology, inflammatory immune responses before ultimately succumbing to the infection. We used the model to evaluate the protective efficacy of nucleoside analogs monulpiravir, favipiravir, ribavirin, the antibiotic tigecycline and the corticosteroids dexamethasone and methylprednisolone against lethal CCHFV infection. Tigecycline, monulpiravir and the corticosteroids failed to protect mice from lethal MA-CCHFV infection. In contrast, f...
Source: Antiviral Research - August 23, 2023 Category: Virology Authors: Thomas Tipih Kimberly Meade-White Deepashri Rao Trenton Bushmaker Mathew Lewis Carl Shaia Heinz Feldmann David W Hawman Source Type: research
The effects of the differentiated macrophages by dexamethasone on the immune responses
Int Immunopharmacol. 2023 Aug 20;124(Pt A):110826. doi: 10.1016/j.intimp.2023.110826. Online ahead of print.ABSTRACTThe characteristics of M2 macrophages suggest immunotherapeutic approaches for inducing immunological tolerance. The current study aimed to evaluate the effect of Dexamethasone (Dex) treatment on monocytes polarization and its impact on immune responses. The monocytes were extracted from the rat's blood samples. The effects of Dex concentration and treatment duration on monocyte viability, phagocytosis of rabbit red blood cell (RRBC) antigens, and cytokine gene expression were evaluated using MTT, ELISA, and ...
Source: International Immunopharmacology - August 22, 2023 Category: Allergy & Immunology Authors: Mohammad Khosravi Hadis MoriBazofti Babak Mohammadian Mohammad Rashno Source Type: research
Intravitreal dexamethasone to manage post endothelial keratoplasty cystoid macular oedema refractory to topical therapy
Eur J Ophthalmol. 2023 Aug 22:11206721231189120. doi: 10.1177/11206721231189120. Online ahead of print.NO ABSTRACTPMID:37605631 | DOI:10.1177/11206721231189120
Source: European Journal of Ophthalmology - August 22, 2023 Category: Opthalmology Authors: Nuno Moura-Coelho Renato Papa-Vettorazzi Jos é L Güell Source Type: research
The effects of the differentiated macrophages by dexamethasone on the immune responses
Int Immunopharmacol. 2023 Aug 20;124(Pt A):110826. doi: 10.1016/j.intimp.2023.110826. Online ahead of print.ABSTRACTThe characteristics of M2 macrophages suggest immunotherapeutic approaches for inducing immunological tolerance. The current study aimed to evaluate the effect of Dexamethasone (Dex) treatment on monocytes polarization and its impact on immune responses. The monocytes were extracted from the rat's blood samples. The effects of Dex concentration and treatment duration on monocyte viability, phagocytosis of rabbit red blood cell (RRBC) antigens, and cytokine gene expression were evaluated using MTT, ELISA, and ...
Source: International Immunopharmacology - August 22, 2023 Category: Allergy & Immunology Authors: Mohammad Khosravi Hadis MoriBazofti Babak Mohammadian Mohammad Rashno Source Type: research
Intravitreal dexamethasone to manage post endothelial keratoplasty cystoid macular oedema refractory to topical therapy
Eur J Ophthalmol. 2023 Aug 22:11206721231189120. doi: 10.1177/11206721231189120. Online ahead of print.NO ABSTRACTPMID:37605631 | DOI:10.1177/11206721231189120
Source: European Journal of Ophthalmology - August 22, 2023 Category: Opthalmology Authors: Nuno Moura-Coelho Renato Papa-Vettorazzi Jos é L Güell Source Type: research
